Marksans Pharma Limited (MARKSANS.NS)
NSE · INR · Healthcare · Drug Manufacturers - General
₹301.40 (+1.60%) as of
Key statistics
- Market cap
- 136.58B
- P/E (TTM)
- 25.54
- Forward P/E
- 21.43
- EPS (TTM)
- 11.80
- Dividend yield
- 0.31%
- 52-week range
- 155.00 – 350.95
- Beta
- 1.15
- Revenue (TTM)
- 31.72B
- Profit margin
- 16.29%
- Analyst target
- ₹324.33
- Volume
- 136.35k
About Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Mumbai, India
- Employees
- 1,685
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.